Who Are the Core Customers in Dynavax Company's Target Market?

Integrated Delivery Networks (IDNs) and chains like CVS and Walgreens drive the bulk of adult vaccination volume and prefer standardized, high-throughput solutions – making them central to the Dynavax target market. In 2025, institutional channel demand accounted for an estimated ~60% of US adult hepatitis B vaccine placements industrywide, underscoring their revenue importance.

Government purchasers including the Veterans Health Administration and Department of Defense represent high-volume, centralized procurement that can shift quarterly supply needs; public health agencies and state immunization programs also buy directly for outbreak response and adult immunization campaigns.

Dynavax core customers are institutional buyers and healthcare providers rather than direct consumers; the company serves a mixed market of hospitals, retail pharmacies, government agencies, and clinics that make commercial and public-health purchasing decisions.

IDNs and retail pharmacy chains are most important by revenue and distribution scale – controlling clinic throughput and shelf placements that drive ongoing repeat purchases. For 2025 commercial planning, prioritizing these Dynavax core customers yields the largest volume and margin upside.

Retail pharmacies account for about 42% of HEPLISAV-B volume as of early 2026, up 12% year-over-year; pharmacies are now the front line for adult immunizations after pandemic-driven behavior shifts.

Public health agencies and hospital purchasing drive demand in states with robust mandates; government vaccine procurement and hospital vaccine purchasing decisions remain meaningful channels for HEPLISAV-B and institutional orders.

Dynavax target market strength is concentrated in adult immunization clinics, retail pharmacies, and commercial buyers; these Dynavax core customers drive most revenue and routine uptake, especially among elderly vaccination demand for hepatitis B vaccine.

Demand for the CpG 1018 adjuvant platform is rising among mid-to-large-cap biotech firms developing shingles, Tdap, and seasonal influenza vaccines; biotech investors and pharmaceutical partners cite the adjuvant's safety profile and immune-boosting performance as key reasons for selection.

Dynavax target market expansion relies on HEPLISAV-B capturing share from three-dose incumbents through aggressive hospital and GPO contracting; by end of 2025 HEPLISAV-B held 44 percent of the US hepatitis B vaccine market. The company broadens reach by licensing CpG 1018 to international vaccine manufacturers and advancing a shingles vaccine candidate to attract adult immunization clinics and elderly vaccination demand.

Retention hinges on the clinical superiority of the CpG 1018 adjuvant, which produces higher seroprotection and shortens dosing compared with older products, creating switching costs once protocols adopt HEPLISAV-B. Contracting with public health agencies and long-term supply agreements with hospital vaccine purchasers lock in volume and predictable revenue, supporting projected 2025 revenues above $340 million.

Repeat demand comes from institutional purchasing cycles – hospital vaccine purchasing decisions and government vaccine procurement for Dynavax products – plus recommendation-driven use by pediatricians and adult immunization clinics. Licensing deals with pharmaceutical partners and distributors deepen the ecosystem, increasing cross-sell opportunities for future pipeline vaccines.

The primary growth lever is HEPLISAV-B's rapid market-share gains via clinical advantage and contracting; this creates durable institutional uptake across Dynavax core customers – healthcare providers, vaccine purchasers, and public health agencies – while adjuvant licensing accelerates international expansion. See further analysis in Growth Outlook of Dynavax Company.